Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Four-month TB therapy proves as effective as 6-month standard regimen

Written by | 24 May 2021

Four months of multi-drug therapy that included rifapentine and moxifloxacin treated active tuberculosis (TB) as effectively as the standard six-month regimen in a multinational study, cutting treatment time… read more.

FDA approves Opdivo as adjuvant treatment in oesophageal or gastroesophageal junction cancer – BMS

Written by | 23 May 2021

Bristol Myers Squibb announced that the FDA has approved Opdivo (nivolumab, injection for intravenous use) for the adjuvant treatment of completely resected esophageal or gastroesophageal junction (GEJ) cancer… read more.

A complex link between body mass index and Alzheimer’s

Written by | 23 May 2021

Though obesity in midlife is linked to an increased risk for Alzheimer’s disease, new research suggests that a high body mass index later in life doesn’t necessarily translate… read more.

New research could lead to better treatment for epilepsy

Written by | 22 May 2021

Scientists have discovered that the way in which neurons are connected within regions of the brain, can be a better indicator of disease progression and treatment outcomes for… read more.

Prophylaxis with ivermectin and the next steps

Written by | 22 May 2021

Interview and article by Christine Clark. Ivermectin should be used for prophylaxis and treatment of covid-19 throughout India, according to Dr Suryakant (Head of the Department of Respiratory… read more.

AstraZeneca COVID-19 vaccine Vaxzevria authorised for emergency use in Japan

Written by | 22 May 2021

AstraZeneca’s COVID-19 vaccine, Vaxzevria (ChAdOx1-S [Recombinant]), formerly AZD1222, has been granted a special approval for emergency use in Japan for active immunisation of individuals aged 18 years and… read more.

Heron Therapeutics announces FDA approval of Zynrelef for the management of postoperative pain for up to 72 hours

Written by | 21 May 2021

Heron Therapeutics, Inc. announced that the FDA has approved Zynrelef (bupivacaine and meloxicam) extended-release solution for use in adults for soft tissue or periarticular instillation to produce postsurgical… read more.

Home isolation and ivermectin-based treatment kits

Written by | 21 May 2021

Interview and article by Christine Clark. Dr Suryakant (Head of the Department of Respiratory Medicine at King George Medical University in Lucknow, India) explains how an ivermectin-based therapy… read more.

How one of the oldest natural insecticides keeps mosquitoes away

Written by | 21 May 2021

Surprisingly, despite widespread use, no one understood exactly how most mosquito repellents keep the insects away. Now researchers are starting to uncover the first pieces of the puzzle…. read more.

FDA grants priority review to Keytruda + Lenvima for advanced endometrial carcinoma – Merck Inc + Eisai

Written by | 20 May 2021

Merck Inc and Eisai announced that the FDA has accepted and granted priority review for an application seeking new approval for the combination of Keytruda (pembrolizumab) plus Lenvima… read more.

The story behind ivermectin use in India

Written by | 20 May 2021

Interview and article by Christine Clark. Dr Suryakant explains how a white paper enabled him and his colleagues to argue the case for ivermectin use and resulted in… read more.

How to predict severe influenza in hospitalized patients

Written by | 20 May 2021

The four-year project took samples from patients hospitalised with influenza at up to five time points during their hospital stay, and 30 days after discharge. They analysed the… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.